Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05279495 · ClinicalTrials.gov registry record · NA

Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers

A NA study of Photoaging, sponsored by MINO Labs.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT05279495 is a NA study of Photoaging that has completed, run by MINO Labs. The registered enrollment target is 20 participants, below the 31-participant average among 14 other Photoaging trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05279495, a NA study of Photoaging, has completed, sponsored by MINO Labs.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Ultraviolet light A (UVA) causes oxidization of guanine to mutagenic 8-Oxoguanine (8-OxoG) and the most frequent and best characterized mutation in mitochondrial DNA (mtDNA), a deletion of 4,977 base pairs, called the "common deletion", a marker of photoaging.

Conditions Studied

Interventions

  • DEVICE In a double-blinded fashion, 250 mg CANNAXR cream
  • DEVICE Topical VEHICLE cream

Study Locations (1)

Florida

  • Center for Clinical and Cosmetic Research - Aventura

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2023-01-15
Est. Completion 2023-05-15
Phase NA

Sponsor

MINO Labs

1 total trials

What the Registry Record Tells You About NCT05279495

The ClinicalTrials.gov registry entry for NCT05279495 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 31-participant average among 14 other Photoaging trials with a reported enrollment target (35% lower). The listed sponsor is MINO Labs, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Photoaging appearing as the primary indexed condition, and to 2 interventions - of which In a double-blinded fashion, 250 mg CANNAXR cream is the first listed.

NCT05279495 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05279495 about?

NCT05279495 is a clinical study titled "Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers". Ultraviolet light A (UVA) causes oxidization of guanine to mutagenic 8-Oxoguanine (8-OxoG) and the most frequent and best characterized mutation in mitochondrial DNA (mtDNA), a deletion of 4,977 base pairs, called the "common deletion", a marker of photoaging.

What is the current status of trial NCT05279495?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2023-01-15. Estimated completion is 2023-05-15.

What conditions does trial NCT05279495 study?

This clinical trial studies the following conditions: Photoaging.

What interventions are being tested in trial NCT05279495?

The interventions under investigation include: In a double-blinded fashion, 250 mg CANNAXR cream (DEVICE), Topical VEHICLE cream (DEVICE).

Who is sponsoring clinical trial NCT05279495?

This trial is sponsored by MINO Labs, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05279495 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Photoaging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.